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between national culture and EQ-5D value sets. Method Rank correlation analysis is 
used to explore relationships between the relative values of a set of EQ-5D states and 
dimensions of national culture. The latter are taken from Hofstede’s framework which 
operationalizes national culture in 5 dimensions. The analysis is carried out using data 
from the countries for which EQ-5D value sets and scores on Hofstede’s dimensions 
of culture both exist: Argentina, Denmark, Germany, Japan, Korea, The Netherlands, 
Poland, Spain, UK, USA. Results Some relationships among the EQ-5D dimensions 
and culture are observed. Eg. the culture dimension: Power-Distance correlates 
strongly with the EQ-5D dimension: Anxiety-Depression (Spearman’s Rho for Power-
Distance indices and TTO valuations of EQ-5D states 11112 and 11113 are 0.523 
and 0.815 respectively). Strong and moderate relationships are observed among other 
culture dimensions (Individualism, Masculinity, Uncertainty-Avoidance) and EQ-5D 
dimensions (Pain, Self-Care). Discussion Different cultures appear to value EQ-5D 
dimensions differently. The correlation patterns observed in this study are generally 
consistent with a priori expectations based on the nature of the dimensions of culture 
and the EQ-5D model. This analysis demonstrates the potential of national culture in 
providing insight into the drivers of the relative values of EQ-5D dimensions for dif-
ferent countries, and in informing decisions about which EQ-5D value sets to use in 
situations where one does not exist.
PR4
ARE HEALTH STATES “TIMELESS”? A TEST OF THE UTILITY 
INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES 
DESIGN AND LATENT GROWTH MODELING
Franic D1, Gafni A2, Vandenberg R1
1University of Georgia, Athens, GA, USA, 2McMaster University, Hamilton, ON, Canada
OBJECTIVES Primary study objective was to test whether individuals’ responses to 
standard gamble (SG) questions do not depend on the duration of time spent in the 
health scenario presented (“timelessness”). Secondary objective of the study was to 
test the “timelessness” of VAS responses. METHODS Face-to-face interviews were 
conducted in a convenience sample of healthy volunteers (n = 59) aged 20 to 63. 
Individuals rated their preferences for three health states of varying post chemotherapy 
nausea and vomiting (PCNV) severity and current health, assuming six different time 
horizons. Repeated measures analysis of variance (RM-ANOVA) was conducted 
(SX6X4X2) to determine the affect of time (6 levels:3 days, 3 months, 1-, 5- and 
20- year(s) and rest of life), health state (4 levels: mild, moderate and severe PCNV 
and current health), and method (2 levels: SG and VAS) on preference. RESULTS 
Results were analyzed using RM-ANOVA and latent growth modeling (LGM). Both 
showed that preferences decreased over time for SG and VAS (p < 0.05). For the 
RM-ANOVA, all main effects and interaction terms were signiﬁcant (p < 0.05). LGM 
showed acceptable ﬁt and signiﬁcant slope parameters for all PCNV. The slopes were 
decreasing over time. Signiﬁcant latent variances for LGM showed that not all indi-
viduals change at the same rate over time (p < 0.05) CONCLUSIONS There is a clear 
advantage in the use of LGM over RM-ANOVA because LGM can evaluate group 
differences in addition to individual changes over time. For the majority of respondents 
the utility independence assumption for SG and VAS did not hold both at the group 
and the individual level. Similar to Bala et al (1999) and Franic et al (2003) the results 
of this study indicated preferences as measured by SG and VAS are not timeless. 
Regardless of the preference measure used: both SG and VAS yield higher preferences 
for shorter time horizons.
PODIUM SESSION I: RISK MANAGEMENT STUDIES
RM1
COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A 
SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65—
TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS
Fowler R, Johnston SS
Thomson Reuters, Washington, DC, USA
OBJECTIVES: Numerous studies have compared risk adjustment measures (RAMs), 
yet none have done so across various outcomes in multiple acute and chronic condi-
tions in a single database with uniform programmatic operationalization. This study 
compares the performance of 7 RAMs and highlights practical programming consid-
erations for hands-on data analysts operationalizing RAMs. METHODS: Data were 
administrative claims from the 2006–2008 MarketScan® Commercial Database. 
Seven RAMs (2 Deyo-Charlson Comorbidity Index variations, Chronic Disease Score 
[CDS], 2 3-digit ICD-9-CM code count variations, number of unique National Drug 
Classiﬁcation [NDC] codes, and number of unique drug molecules) measured over a 
1-year baseline period were compared in 7 conditions (acute coronary syndrome, 
sample N = 14,951; rheumatoid arthritis [RA], N = 27,085; depression, N = 129,206; 
diabetes, N = 126,087; hypertension, N = 225,080; asthma, N = 56,172; ﬁbromyalgia, 
N = 52,365) on the basis of 3 outcomes (total health care cost, emergency room [ER] 
visits, inpatient admissions) measured over a 1-year follow-up period. Goodness-of-ﬁt 
statistics (chi-squared statistic for total health care costs and c-statistic for ER visits 
and inpatient admissions) were compared across age and sex-adjusted regression 
models for each individual RAM. RESULTS: A unique 3-digit ICD-9-CM code count 
that excluded ‘rule-out’ diagnoses consistently outperformed, i.e., had highest chi-
squared and c-statistics, every other RAM in every condition and outcome with the 
exception of the number of unique NDC codes, which performed the best for all 
outcomes in depression and ﬁbromyalgia patients. The number of unique NDC codes 
was generally the second-best performing RAM across all outcomes. The CDS per-
formed worst across every condition and outcome. CONCLUSIONS: Complex RAMs 
are subject to inconsistencies in their operationalization and application from a pro-
gramming perspective. Across multiple acute and chronic conditions, the two simplest 
and programmatically-transparent RAMs were the most predictive measures of total 
health care cost, ER visits, and inpatient admissions.
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IMPACT OF ADHERENCE WITH STATIN THERAPY ON 
HOSPITALIZATION RISK AND MORTALITY AMONG PATIENTS  
WITH DIABETES
Yang Y, Banahan BF, Pace PF
University of Mississippi, University, MS, USA
OBJECTIVES: The objective of this study was to evaluate the impact of adherence 
with statin therapy on diabetes-speciﬁc hospitalization and all-cause mortality among 
patients with diabetes enrolled in a state Medicaid program. METHODS: The authors 
conducted a retrospective cohort study of patients with diabetes who were continu-
ously enrolled in a state Medicaid program from January 2002 to December 2004. 
The date of the ﬁrst medication claim for statin during the ﬁrst six months of 2002 
was the index date. Adherence to statin was assessed within one year following the 
index date. Adherence was assessed using the proportion of days covered (PDC) and 
patients with a PDC of 0.8 or greater considered being adherent. The primary out-
comes of interest were diabetes-speciﬁc hospitalization and all-cause mortality during 
the follow-up period (end of adherence measurement to December 31, 2004). Multi-
variate regression analyses were performed to assess the impact of adherence with 
statin therapy on outcome measures. RESULTS: A total 10,839 patients were included 
in the study. Mean age 60.3 ± 10.0 years, 23.8% male, 76.2 female; 31.7% white, 
50.4% black. At 12 months after the index prescription, only 23.9% of patients were 
adherent with their prescribed statin therapy. During follow-up After controlling for 
age, gender, race, prior hospitalization, and Charlson comorbidity index, patients who 
were adherent to statin therapy were 48.7% (OR: 0.513; 95%CI: 0.421–0.624) less 
likely to have diabetes-speciﬁc hospital admissions in comparison to nonadherent 
patients. Adherence with statin therapy had no statistically signiﬁcant impact on all-
cause mortality (OR: 0.801; 95%CI: 0.454–1.412). CONCLUSIONS: Adherence 
with statin therapy was poor among patients with diabetes enrolled in a Medicaid 
program. Adherence with statin therapy was associated with signiﬁcantly less risk for 
diabetes-speciﬁc hospitalization. Greater efforts are needed to facilitate diabetes self-
management behaviors to improve patient outcomes.
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RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING 
ATIPSYCHOTIC AGENTS- A PROPENSITY-MATCHED RETROSPECTIVE 
COHORT STUDY
Mehta S, Aparasu RR, Chen H, Johnson M
University of Houston, Houston, TX, USA
OBJECTIVES: To examine the risk of falls/fractures associated with atypical antipsy-
chotic use compared to typical antipsychotic use in community dwelling older adults. 
METHODS: The population based retrospective cohort analysis based on propensity 
score matching was conducted using IMS LifeLink™ Health Plan claims data. Patients 
were included in the cohort if they met following criteria: ≥ 50 years of age, new users 
of atypical or conventional antipsychotics who began taking antipsychotics between 
July 2000 and December 2007, and continuously enrolled for six months before and 
at least six months after initiation of antipsychotic treatment. Patients taking atypical 
antipsychotics were matched with those using typical antipsychotics using propensity 
score greedy matching technique. Kaplan-Meier survival curves and Cox proportional 
hazard model stratiﬁed on matched pair was employed to examine risk of hospitaliza-
tion/emergency visit due to falls or femur fractures within one year. Duration of 
antipsychotic therapy and exposure to other psychotropic medications were controlled 
for in the ﬁnal model. RESULTS: A total of 11,160 older adults (5,580 atypical and 
5,580 typical users) were identiﬁed as new users of antipsychotics after matching. 
Within one year of follow up period, 456 patients (8.06 %) in atypical drug group 
had falls/femur fractures compared to 375 (6.72%) in typical antipsychotic group. No 
signiﬁcant difference was found between atypical users compared to typical agents 
with respect to risk of falls/fractures [Hazard Ration (HR) 1.01, 95% CI 0.83–1.22]. 
However, duration of therapy more than 90 days was signiﬁcantly (HR, 1.81, CI, 
1.35–2.43) associated with increased risk of falls/fractures compared to less than 30 
days. CONCLUSIONS: The study results show no signiﬁcant difference in the risk of 
falls/fractures between atypical and typical antipsychotic use among older adults. 
However, there is a need to be cautious while prescribing atypical and typical anti-
psychotics in older adults for longer periods of time.
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CONFOUNDING EFFECT OF AGE IN THE ASSOCIATION OF 
CARDIOVASCULAR RISK AND DIETARY SUPPLEMENT USE  
AMONG US ADULTS
Yu S, Shaw JW, Crawford SY, Groo V
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Dietary supplement (DS) use has been found to be associated with 
cardiovascular disease (CVD) risk. This study assessed whether age moderates or 
confounds the association between CVD risk and DS use. METHODS: Data were 
taken from the 1999–2004 waves of the National Health and Nutrition Examination 
Survey. Inferences were restricted to US population members ≥20 years of age as 
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represented by 15,332 survey participants. Participants were classiﬁed according to 
CVD risk as diseased (history of coronary heart disease, angina, and/or myocardial 
infarction), at-risk (history of hyperlipidemia, hypertension, and/or diabetes mellitus), 
or low-risk (no history of any conditions). They were also classiﬁed according to the 
reported use of single-ingredient DSs including niacin, coenzyme Q10, ﬁsh oil, garlic, 
vitamin C, and vitamin E during the month prior to survey. Tests of moderation and 
confounding by age were performed. RESULTS: The prevalence of use of any of the 
six DSs increased with age. Odds ratios for any DS use for the at-risk and diseased 
groups, relative to the low-risk group, were 1.91 (95% CI: 1.67–2.17) and 2.25 (95% 
CI: 1.88–2.69), respectively. With adjustment for age, these became 1.32 (95% CI: 
1.15–1.52) and 1.20 (95% CI: 0.99–1.44), respectively. There was no evidence of 
moderation (p = 0.123), though confounding was present (p < 0.001). CONCLU-
SIONS: There is a potential for residual confounding by age in studies of CVD risk 
and DS use. After adequately controlling for age in this study, the relationship between 
CVD risk and DS use was greatly attenuated. The ﬁndings indicated different patterns 
of responses to cardiovascular disease risk between younger adults and older ones in 
terms of DS consumption. Awareness of the confounding effect of age in the associa-
tion of CVD risk and DS use should be noted in clinical practice and health 
promotion.
PODIUM SESSION II: COST-EFFECTIVENESS STUDIES
CE1
COST-EFFECTIVENESS OF SWITCHING PATIENTS WITH TYPE 2 
DIABETES FROM INSULIN GLARGINE TO INSULIN DETEMIR IN A 
CHINESE SETTING: A HEALTH ECONOMIC MODEL BASED ON THE 
PREDICTIVE STUDY
Yang L1, Christensen T2, White J3, Sun F4
1Peking University Health Science Center, Beijing, China, 2Novo Nordisk A/S, Virum, 
Denmark, 3Novo Nordisk, Zurich, Switzerland, 4Novo Nordisk (China) Pharmaceuticals Co., 
Ltd., Beijing, China
OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from insulin 
Glargine (IGla) to Insulin Detemir (IDet) in type 2 diabetes patients in the setting of 
Chinese tier 3 hospitals. METHODS: A published and validated computer simulation 
model of diabetes (the CORE Diabetes Model) was used to make the long- term (30 
years) projection of health economic outcomes. Patient demographic information and 
clinical endpoints were derived from a subgroup analysis of the PREDICTIVE study. 
PREDICTIVE was a large, multi-centre, 6 months observational study assessing the 
safety and efﬁcacy of IDet in everyday clinical practice. HbA1c was reduced of 0.59 
% by switching from IGla to IDet. Baseline risk factors and racial characteristic data 
were obtained from Chinese cohort studies. The market retail prices of medications 
were calculated to estimate treatment costs. The diabetes management and complica-
tions costs were obtained from Chinese published data and adjusted to 2009 values 
using the Chinese Consumer Price Index. An annual discounting rate of 3% was used 
for both health and cost outcomes according to the recommendation of Chinese 
Pharmacoeconomics guideline. One-way sensitivities analysis was performed and illus-
trated that the results were robust. RESULTS: Conversion to IDet from IGla was 
projected to improve patient life expectancy by 0.09 year and 0.36 quality adjusted 
life years (QALYs). Treatment costs, and management costs were increased of 4,004 
(84,047 vs 80,043), 243 (28,913 vs 28,670) Chinese Yuan (CNY) respectively. 
However, the costs of complications including CVD, renal, ulcer/amputation/neuropa-
thy, eye and hypoglycaemia events were reduced by 4,931 CNY (89,628 vs 94,559), 
resulting in a total direct medical cost saving of 684 CNY when converting to IDet. 
CONCLUSIONS: Conversion to IDet from an IGla regimen improved life-expectancy 
and was a cost-saving treatment approach in a Chinese setting.
CE2
COST-EFFECTIVENESS OF SILDENAFIL IN THE MANAGEMENT OF 
PULMONARY ARTERIAL HYPERTENSION IN MEXICAN ADULT 
PATIENTS
Arreola-Ornelas H1, Rosado-Buzzo A1, García-Mollinedo L1, Dorantes-Aguilar J1, 
Muciño-Ortega E2, Mould-Quevedo JF2
1Links & Links, Mexico City, Mexico, 2Pﬁzer S.A. de C.V., México City, Mexico
OBJECTIVES: Pulmonary arterial hypertension (PAH) is a clinical condition that 
causes decreased exercise tolerance and heart failure. The aim of this study was to 
assess the cost-effectiveness of different drugs to manage PAH in adult, functional 
class III, patients, who have failed previously to calcioantagonists, from the health 
care payer’s perspective. METHODS: A ﬁve-state Markov model was performed to 
estimate one year costs and health consequences (1-month cycles). Effectiveness mea-
sures were quality-adjusted life years (QALY’s) gained, as well as reduction in hospital 
length of stay (LOS) and discontinuation rate due to adverse events. Transition prob-
abilities were obtained from a meta-analysis involving national and international 
published literature. Doses of comparators used in the assessment were sildenaﬁl 
(60 mg/day); bosentan (250 mg/day); sitaxsentan (100 mg/day) and ambrisentan 
(5 mg/day, reference alternative). Resource use and costs were obtained from hospital 
records (n = 110) from the Social Security Mexican Institute. Costs include hospital 
stay, laboratory and respiratory function tests, imagenology, drugs and adverse events 
management. The model was validated according to international guidelines. Sensitiv-
ity analyses were performed employing bootstrapping techniques and acceptability 
curves were constructed. RESULTS: Per patient associated costs for sildenaﬁl, bosen-
tan, sitaxsentan and ambrisentan were [CI 95%]: US$16,840 [US$16,590–US$17,176], 
US$38,068 [US$37,725–US$38,497], US$40,203 [US$39,888–US$40,647] and 
US$26,146 [US$25,898–US$26,479], respectively. Sildenaﬁl is associated to the 
highest gain in QALY’s: 0.1 [−0.01–0.22], as well as to the main reduction in discon-
tinuation rate: 89.25 [89.11%-89.4%] and reduction in LOS: 8.64 days [8.53 days–
8.75 days], respectively. In consequence, sildenaﬁl represents the most attractive 
therapy to manage PHA in terms of cost-effectiveness. CONCLUSIONS: In the 
Mexican institutional setting, sildenaﬁl demonstrated to be a cost-saving therapy to 
manage PHA in adult, functional class III patients. These results should be taken into 
account by Mexican health professionals to generate efﬁcient resource allocation 
strategies.
CE3
COST-EFFECTIVENESS OF POLYMYXIN B IMMOBILIZED FIBER 
COLUMN AND CONVENTIONAL MEDICAL THERAPY IN THE 
MANAGEMENT OF SEVERE ABDOMINAL SEPSIS IN ITALY
Berto P1, Antonelli M2, Ronco C3, Cruz D3, Melotti RM4
1Pbe Consulting, Verona, Italy, 2Università Cattolica del Sacro Cuore—Policlinico Gemelli, 
Roma, Italy, 3Ospedale San Bortolo, Vicenza, Italy, 4Università di Bologna, Bologna, Italy
OBJECTIVES: Severe abdominal sepsis and septic shock (SAS-SS) are common prob-
lems in intensive care units (ICU), and carry high mortality. This study assessed the 
cost-effectiveness of Polymyxin B immobilized ﬁber column (PMX) plus conventional 
therapy (CT) (PMX-CT) versus CT alone, for SAS-SS, in the perspective of the Italian 
NHS (hospital). METHODS: This study was a retrospective cost-effectiveness analysis 
(CEA) with clinical efﬁcacy and consumption of resources collected alongside an RCT 
(Cruz et al. JAMA 2009). 64 SAS-SS patients were enrolled following emergency 
surgery for intra-abdominal infection in 10 tertiary care ICUs, from 12/2004 
to12/2007. Costs included: hospital days, ICU days; catecholamine treatment days; 
renal replacement therapy (RRT) days; mechanical ventilation treatment (MVT) days; 
use of PMX device. Resources were valued using published tariffs and market values. 
All-cause hospital mortality was extrapolated to survival (expected life-years per 
patient/arm): for each survivor average life expectancy (in years) by age and sex was 
retrieved from National Life Tables; for deceased patients, only the number of survival 
days as reported in the CRF, was retained. Per patient survival was then weighed using 
a predicted death rate based on individual Apache II scores, to account for disease 
severity. Univariate sensitivity analyses on costs and outcomes and 2000 Bootstrap 
simulations were run to test CEA’s results. RESULTS: Based on the expected number 
of survival years (PMX-CT 8.24/patient, CT 4.69/patient), the mean difference in 
survival yielded an expected increase of 3.55LYG/patient for PMX-CT, at the addi-
tional cost of 313,411/patient with a mean ICER of 33,774/LYG and a median ICER 
of 32,776/LYG. Results of the base-case CEA were conﬁrmed by all sensitivity analyses 
with ICER values always well below commonly accepted value thresholds.CONCLU-
SIONS: PMX-CT vs. CT is a cost-effective intervention for treatment of severe abdom-
inal sepsis and septic shock and should be considered for use in the Italian NHS’ 
hospital setting.
CE4
A PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF TARGETED 
VACCINATION POLICIES TO MITIGATE THE IMPACT OF THE H1N1 
PANDEMIC IN THE US
Hettle R, Reason T
Heron Evidence Development Ltd, Luton, Bedfordshire, UK
OBJECTIVES: Under the circumstances of a severe pandemic and constrained research 
and manufacturing capacity, the need to appropriately deploy vaccination stockpiles 
becomes critical. The objective of this study was to provide insight into the most 
cost-effective vaccination strategy when under constrained circumstances. METHODS: 
A deterministic and compartmental SIR (Susceptible-Infected-Removed) cost-effective-
ness model was developed from a US CDC perspective using Microsoft Excel. The 
model consists of 6 distinct age groups, integrated by a contact matrix. The infectivity 
of the pandemic was based on reported CDC estimates, with the model calibrated 
accordingly. A 75% vaccination efﬁcacy was used, consistent with previous studies. 
Under the assumption of stockpiling 50 million doses of vaccine, vaccination strategies 
were assessed in terms of infections avoided during the estimated 17 month period of 
the pandemic. The scenarios included strategies targeted to speciﬁc age groups: indi-
vidually targeted age groups, groups under 20, over 20, 20–59 and 0–12 and 60+ 
combined. Costs were limited to vaccine acquisition, with the total rate of vaccination 
per day estimated at 741,935. For the base case, we initiate the pandemic in May 
2009 and began vaccination in October. Sensitivity analysis on the initiation of vac-
cination was also assessed. RESULTS: With no vaccination, a basic reproduction 
number of 1.3 and infectious period of 4.5 days yielded an attack rate of 27.7%.The 
cost-effectiveness of targeted vaccination ranged from $4.87 (13–19 years) to $67.05 
(65+) per infection avoided. Under the criteria of exhausting vaccine supplies, the most 
cost-effective strategy was to target those under 20 years old ($10.77 per infection 
avoided). Initiating vaccination earlier during a pandemic marginally improved cost-
effectiveness, while delayed vaccination resulted in substantially reduced cost-effec-
tiveness. CONCLUSIONS: Administering vaccinations to those aged under 20 years 
is the most cost-effective strategy. All vaccination policies initiated after the peak of 
the pandemic, were less cost-effective.
